The Sunday Times's Sabah Meddings told readers to 'buy' shares of Royal Mail Group.
Pfizer’s most senior UK executive has criticised the call to forgo patents on Covid vaccines, warning that it would lead to a global shortage of raw materials. Ben Osborn, who leads the American drugs giant in the UK, said an intellectual-property waiver was “not the answer”. “We would see a very rapid short-term impact,” he said. “It could allow any organisation to start procuring some of these basic raw materials across multiple countries. ” Osborn, 44, said it could even mean that existing vaccine manufacturers — which include Astra Zeneca and US biotech venture Moderna — would be unable to fulfil their obligations to deliver doses.
Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.